Skip to main content

Advertisement

Table 5 Treatment exposure in responders and non-responders

From: Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

  WT KRAS(n = 85) MT KRAS(n = 58) Overalla (n = 152)
  Responders (n = 48) Non-responders (n = 37) Responders (n = 22) Non-responders (n = 36) Responders (n = 75) Non-responders (n = 77)
Panitumumab cycles delivered – mean (SD) 16.3 (6.6) 9.2 (6.9) 15.0 (6.4) 8.5 (4.4) 15.8 (6.6) 8.7 (5.7)
Cumulative panitumumab dose deliveredb, mg/kg - mean (SD) 94.2 (37.0) 55.2 (41.5) 83.5 (37.4) 49.8 (26.2) 89.8 (37.5) 51.4 (34.2)
Irinotecan cycles delivered mean (SD) 15.6 (6.0) 9.5 (6.3) 15.7 (4.8) 9.3 (4.5) 15.5 (5.7) 9.4 (5.4)
Cumulative irinotecan dose deliveredb, mg/kg - mean (SD) 2635 (1012) 1614 (1026) 2603 (754) 1542 (722) 2605 (954) 1569 (869)
  1. Responders comprise those patients with a best overall response of a complete or partial response; non-responders comprise those patients with a best overall response of stable disease, disease progression or those with no post-baseline response assessment.
  2. aAll patients in the tumour response analysis set regardless of KRAS evaluability; bAdjusted for weight or BSA (most recent measurement before infusion).